(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 34.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Tarsus Pharmaceuticals's revenue in 2025 is $295,521,000.On average, 4 Wall Street analysts forecast TARS's revenue for 2025 to be $17,642,541,321, with the lowest TARS revenue forecast at $16,742,114,440, and the highest TARS revenue forecast at $18,204,411,071. On average, 3 Wall Street analysts forecast TARS's revenue for 2026 to be $23,875,580,714, with the lowest TARS revenue forecast at $19,625,760,020, and the highest TARS revenue forecast at $28,470,881,651.
In 2027, TARS is forecast to generate $30,493,359,469 in revenue, with the lowest revenue forecast at $30,478,584,532 and the highest revenue forecast at $30,508,134,406.